Tandem Diabetes Care, Inc. (TNDM) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Tandem Diabetes Care (TNDM) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Tandem is a medical-device company that makes insulin pumps, including the t:slim X2 and the miniaturized Tandem Mobi, paired with its Control-IQ+ automated insulin delivery software and continuous glucose monitors from Dexcom and Abbott. As of October 16, 2026 the stock closed near $17, down about 21% year to date but up about 11% over one year, for a market value of roughly $1.2 billion. The bull case is a growing installed base (around 324,000 U.S. customers at the end of 2025), recurring supply revenue, a Mobi rollout that reached twelve international markets in September 2026, and a 2026 turn toward positive adjusted EBITDA. The biggest risks are intense competition from Insulet's Omnipod and Medtronic, the unproven impact of GLP-1 weight-loss drugs on long-term pump demand, and a company still posting GAAP net losses (about $63 million over the trailing twelve months).
TNDM stock price
As of 2026-11-16, Tandem Diabetes Care, Inc. (TNDM) last closed at $18.48, up 0.8% over the past year. Over the past 52 weeks it has traded between $12.82 and $28.26.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Tandem Diabetes Care, Inc.'s investor relations page. Walnut is informational, not investment advice.
TNDM key stats
At $18.48 on November 16, 2026, Tandem Diabetes Care, Inc. (TNDM) has a market cap of $1.3B.
- Market cap
- $1.3B
- P/E (forward)
- 138.1
- Price to book
- 9.5
- Beta
- 1.60
Market cap, P/E and yield are measured at the $18.48 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Tandem Diabetes Care, Inc. (TNDM)?
The last two weeks for Tandem Diabetes Care, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- TNDM closed at $18.48 on November 16, 2026, up 1.7% over the past five trading days (from $18.17).
- On November 13, 2026, Tandem Diabetes Care, Inc. filed an 8-K with the SEC reporting other events (Item 8.01). Read the 8-K on sec.gov
- On November 5, 2026, Tandem Diabetes Care, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 5, 2026, Tandem Diabetes Care, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 6, 2026, Barclays raised its target to $20.00 from $18.00 (Equal-Weight).
- On November 6, 2026, Wells Fargo lowered its target to $25.00 from $27.00 (Overweight).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Tandem Diabetes Care, Inc. (TNDM) latest quarter
Tandem Diabetes Care reported revenue of $284 million for Q3 2026, up 14% from a year earlier (Tandem Diabetes Care, Nov 5, 2026).
Source: Tandem Diabetes Care Q3 2026 results, Nov 5, 2026. Full earnings breakdown
What does Tandem Diabetes Care, Inc. (TNDM) do?
Tandem Diabetes Care designs, makes, and sells insulin pumps for people with diabetes. Its flagship products are the t:slim X2 pump and the much smaller Tandem Mobi system, both running Control-IQ+ automated insulin delivery software that reads data from a continuous glucose monitor (CGM) and automatically adjusts insulin dosing. The business works on a razor-and-blade model: Tandem earns an up-front sale when a customer adopts a pump, then recurring revenue from the disposable cartridges, infusion sets, and other supplies that customer buys for years afterward. Pumps integrate with third-party CGMs from Dexcom (G6/G7) and Abbott (FreeStyle Libre), which Tandem does not make itself.
The company shipped its first t:slim pump in 2012 and built its lead through software, releasing Control-IQ automation and then Control-IQ+, which was cleared for commercial use in 2025 and expanded to younger patients and additional indications. The Tandem Mobi, the company's smallest pump, has been ramping in the U.S. and, since late September 2026, is available in twelve international markets, with Android phone control added in the 2025-2026 window. Tandem competes in a crowded automated insulin delivery market against Insulet's tubeless Omnipod 5, Medtronic's MiniMed 780G, Beta Bionics' iLet, and newer entrant Sequel Medtech's twiist, which launched in 2025. It is also working through a shift toward a pay-as-you-go (PayGo) pharmacy-channel model that creates near-term pricing headwinds.
In the second quarter of 2026 Tandem reported revenue of about $254.6 million, up roughly 6% from a year earlier, and a loss of $0.31 per share, a penny better than the -$0.32 consensus. That followed a first quarter in which the loss of $0.30 per share beat the -$0.44 estimate by a wider margin. Over the trailing twelve months revenue was about $1.04 billion, gross margin about 56%, and the net loss about $63 million, much smaller than the full-year 2025 loss.
What's driving Tandem Diabetes Care, Inc. (TNDM)?
1. Recurring supplies and a growing installed base.
Tandem ended 2025 with a U.S. installed base of roughly 324,000 customers, each generating recurring revenue from pump supplies long after the initial sale. Worldwide sales reached about $1 billion for full-year 2025 and about $1.04 billion over the twelve months to June 2026. This razor-and-blade dynamic gives the business a growing, relatively predictable revenue stream that compounds as more pumps are placed and renewed.
2. Tandem Mobi and Control-IQ+ product cycle.
The miniaturized Tandem Mobi, billed as the world's smallest durable automated insulin delivery system, has been ramping in the U.S., and on September 28, 2026 Tandem said it was available in twelve international markets; the shares rose about 7% around that launch. Android phone control was added in 2025-2026, and Control-IQ+ software was cleared for commercial use in 2025 and broadened to younger patients. These launches are central to keeping Tandem competitive against tubeless and patch-pump rivals.
3. International growth and CGM integrations.
International pump shipments rose to more than 40,000 for full-year 2025, an increasingly important growth lever, and the twelve-market Mobi rollout adds a second product to that channel. Tandem also began the global rollout of t:slim X2 integration with Abbott's FreeStyle Libre 3 Plus sensor, adding to existing Dexcom G6/G7 support. Wider sensor choice can broaden Tandem's addressable customer base across geographies.
4. Turn toward profitability.
Full-year 2025 non-GAAP gross margin was about 54%, with the fourth quarter at roughly 58%, and Q4 2025 adjusted EBITDA was positive at about $32.9 million (11% of sales). For 2026 management guided to gross margins of 56% to 57% and full-year positive adjusted EBITDA of 5% to 6%, though revenue growth is tempered by a $70 million to $80 million pricing headwind from the PayGo transition. Trailing gross margin has reached about 56%, inside that range, and analysts expect a small profit of about $0.18 per share in the fourth quarter of 2026 and about $0.16 per share for full-year 2027.
What are the risks to Tandem Diabetes Care, Inc. (TNDM)?
Competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share. GLP-1 weight-loss drugs are a structural unknown that management has acknowledged may have weighed on the broader insulin-therapy market since 2023, though the long-term effect on pump demand is unclear. Tandem still posts GAAP net losses (about $63 million over the trailing twelve months, after about $204.7 million in 2025), burned roughly $44 million of free cash flow over that period, and carries about $739 million of debt against about $456 million of cash. It must execute its PayGo pharmacy-channel transition without losing customers, while reimbursement decisions and product execution on Mobi and new integrations all carry uncertainty. Analysts have trimmed targets too: Truist cut its price target to $28 from $31 in September 2026 while keeping a Buy rating.
What is the Tandem Diabetes Care, Inc. (TNDM) forecast?
21 analysts publish price targets on TNDM, averaging $27.38 as of November 2026, or +48.2% against the $18.48 share price on November 16, 2026. The published targets run from $18.00 to $50.00, a wide spread, and the ratings split 13 buy, 12 hold, 0 sell. Over the last six months there have been 3 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full TNDM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is TNDM a buy or a sell?
We give no verdict on Tandem Diabetes Care, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Recurring supplies and a growing installed base. Tandem ended 2025 with a U.S. The most optimistic published target, $50.00, assumes this works close to its best case.
The case against. Competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share. The most pessimistic target, $18.00, is roughly what TNDM is worth if this bites instead.
Read the full bull and bear case on TNDM, including what would have to change to break either one. Walnut is not an investment adviser.
Has Tandem Diabetes Care, Inc. (TNDM) split its stock?
Yes. Tandem Diabetes Care, Inc. (TNDM) has had one share split in the last 10 years:
- 1:10 on October 10, 2017, so every share held became 0.1 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of TNDM the day before the 1:10 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Tandem Diabetes Care, Inc. (TNDM) valued?
Market cap, P/E and dividend yield at today's price are in the TNDM key stats above. The business figures below come from Tandem Diabetes Care, Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$1.04 billion
- Revenue growth (latest quarter): ~6% year over year (Q2 2026: ~$254.6M)
- Gross margin (TTM): ~56%; operating margin ~-5%
- Net income (TTM): ~-$63 million; EPS ~-$0.91
As of October 2026: Tandem is best read as a growth medtech rather than a mature, profitable company, so investors tend to watch pump shipments, installed-base growth, gross margin, and the path to positive adjusted EBITDA rather than a simple P/E ratio. At about 1.1 times trailing sales and roughly $1.2 billion in market value, the shares price in modest expectations for a business that analysts see moving to small profits in 2027; the forward P/E near 107 mostly reflects how thin those projected earnings still are. Third-quarter results on November 5, 2026 come with a consensus of about $265.9 million in revenue and a loss of $0.24 per share.
Who competes with Tandem Diabetes Care, Inc. (TNDM)?
Insulin-pump and AID peers
Insulet (PODD), maker of the tubeless Omnipod 5, is Tandem's most direct and fastest-growing competitor; Medtronic Diabetes sells the MiniMed 780G; and newer automated insulin delivery players include Beta Bionics' iLet and Sequel Medtech's twiist, which launched in the U.S. in 2025.
CGM partners and adjacent device makers
Dexcom (DXCM) and Abbott (ABT) supply the continuous glucose monitors that Tandem pumps integrate with, making them partners rather than rivals, but they shape the ecosystem and economics around automated insulin delivery.
ETFs and diversified alternatives
Investors who want exposure to medical devices without single-stock risk can look at funds such as the iShares U.S. Medical Devices ETF (IHI) or broad health-care ETFs, which may hold TNDM alongside larger device makers.
What stocks are similar to Tandem Diabetes Care, Inc. (TNDM)?
Other names that sit close to TNDM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Tandem Diabetes Care, Inc. (TNDM)
There are three common ways to get TNDM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so TNDM sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where TNDM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Tandem Diabetes Care, Inc. (TNDM)
Tandem is a growth medtech story: an insulin-pump maker at roughly $1.04 billion in trailing sales, transitioning toward consistent profitability on the back of its installed base and recurring supplies. GAAP losses have narrowed sharply from 2025's roughly $205 million, but revenue growth in the latest quarter was only about 6% as the PayGo pricing shift bites. The stock tends to be volatile and competition-sensitive, swinging on pump shipment trends, new product ramps like Mobi, and worries about Omnipod, Medtronic, and GLP-1 drugs. It trades around 1.1 times sales, and the next test is third-quarter results on November 5, 2026.
More on Tandem Diabetes Care, Inc. (TNDM)
Whether TNDM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TNDM a buy or a sell?, and where the stock could go from here in the TNDM stock forecast.
For income investors, whether TNDM pays a dividend and how the payout looks is covered in does TNDM pay a dividend? And to weigh TNDM against a peer, read the full side-by-side comparisons: TNDM vs PODD and TNDM vs MDT.
Wondering how TNDM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Tandem Diabetes Care, Inc.
Ask Walnut's AI anything about TNDM and see how it fits what you own.
FAQ
What does Tandem Diabetes Care do?
+
Tandem Diabetes Care makes insulin pumps for people with diabetes, led by the t:slim X2 pump and the miniaturized Tandem Mobi system. Both run its Control-IQ+ automated insulin delivery software, which uses data from a continuous glucose monitor to adjust insulin automatically. Tandem earns money from selling pumps and, over time, from the recurring disposable supplies those pumps require, which added up to about $1.04 billion of revenue over the twelve months to June 2026.
Does TNDM pay a dividend?
+
No. Tandem Diabetes Care does not pay a dividend. As a growth-stage medical-device company still working toward consistent profitability (it lost about $63 million over the trailing twelve months), it reinvests cash into research, product launches, and scaling its business, so any shareholder return would come from share-price changes rather than dividend income.
Is TNDM a good stock?
+
This is descriptive, not advice. The bull case is a growing installed base of around 324,000 U.S. customers, recurring supply revenue, new products like Mobi (now in twelve international markets) and Control-IQ+, and a 2026 turn toward positive adjusted EBITDA. The bear case is heavy competition from Omnipod and Medtronic, uncertain GLP-1 drug effects on pump demand, single-digit revenue growth during the PayGo transition, and continuing GAAP net losses. As of October 2026, 21 analysts tracked by Yahoo Finance rate it a Buy on average with a mean target near $27.76, though targets are opinions, not forecasts. Whether it fits you depends on your own goals and risk tolerance.
Is TNDM a good stock to buy right now?
+
This is informational, not a recommendation. TNDM tends to be volatile and competition-sensitive, reacting to pump shipment trends, product ramps, gross-margin progress, and news about rivals or GLP-1 drugs. In 2026 it has ranged between about $12.26 and $29.65 over the past 52 weeks and closed near $17 on October 16, down about 21% year to date. Some investors focus on its path to profitability and installed-base growth, while others worry about market share and the PayGo pricing transition. Walnut provides information, not investment advice.
How does competition from Insulet's Omnipod affect Tandem?
+
Insulet's Omnipod 5 is a tubeless, fully disposable patch pump and the fastest-growing system in the market, competing directly with Tandem's t:slim X2 and Mobi. Strong Omnipod growth can pressure Tandem's new-pump share and pricing. Tandem's response includes the smaller Mobi form factor, Control-IQ+ software, and broader CGM integrations, plus its own patch-pump development.
Could GLP-1 weight-loss drugs hurt insulin pump demand?
+
It is a genuine uncertainty. Tandem's management has acknowledged that GLP-1 medications may have weighed on the broader insulin-therapy market since around 2023. Most of Tandem's customers have type 1 diabetes and still require insulin, but the long-term effect of GLP-1 drugs on type 2 insulin use and pump adoption is not yet clear, which is part of why the stock can be volatile.
What is the Tandem Mobi pump?
+
The Tandem Mobi is Tandem's smallest insulin pump, marketed as the world's smallest durable automated insulin delivery system. It runs Control-IQ+ software, can be controlled from a compatible smartphone (with Android control added in the 2025-2026 window), and is designed to compete with discreet tubeless and patch-style pumps. On September 28, 2026 Tandem said Mobi was available in twelve international markets, so its U.S. and international ramp is a key part of Tandem's growth story.
Which ETFs or baskets include TNDM?
+
Tandem can appear in medical-device and health-care ETFs, such as the iShares U.S. Medical Devices ETF (IHI), and in some small- and mid-cap or growth-oriented funds, depending on each fund's methodology and size cutoffs. On Walnut you can also hold TNDM as one constituent of a thematic basket, for example a diabetes-technology or medtech theme, alongside related companies.
How did Tandem Diabetes Care do in its latest quarter?
+
For the second quarter of 2026 (ended June 30), Tandem reported revenue of about $254.6 million, up roughly 6% year over year, and a net loss of about $21.2 million, or $0.31 per share, slightly better than the -$0.32 analysts expected. The company has now topped the EPS consensus in each of its last four reported quarters. Third-quarter results are scheduled for November 5, 2026, with consensus near $265.9 million in revenue and a loss of $0.24 per share.
How has TNDM stock performed in 2026?
+
As of the October 16, 2026 close near $17, TNDM was down about 21% year to date and up about 11% over the prior twelve months, with a 52-week range of roughly $12.26 to $29.65. Over the last three months it slipped about 3%. The shares rose about 7% around the late-September international Mobi launch but remain well below their 52-week high, as investors weigh slow revenue growth during the PayGo transition against narrowing losses.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Tandem Diabetes Care, Inc.'s investor relations page or your broker before making investment decisions.